These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 15919466

  • 21. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
    Wagner K, Webber SA, Kurland G, Boyle GJ, Miller SA, Cipriani L, Griffith BP, Fricker FJ.
    J Heart Lung Transplant; 1997 Mar; 16(3):275-82. PubMed ID: 9087870
    [Abstract] [Full Text] [Related]

  • 22. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab.
    Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC.
    Transplant Proc; 2006 Jun; 38(5):1307-13. PubMed ID: 16797289
    [Abstract] [Full Text] [Related]

  • 23. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study.
    Pankewycz O, Leca N, Kohli R, Weber-Shrikant E, Said M, Alnimri M, Feng L, Patel S, Laftavi MR.
    Transplant Proc; 2011 Mar; 43(2):519-23. PubMed ID: 21440749
    [Abstract] [Full Text] [Related]

  • 24. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results.
    Schulz T, Flecken M, Kapischke M, Busing M.
    Transplant Proc; 2005 May; 37(4):1818-20. PubMed ID: 15919476
    [Abstract] [Full Text] [Related]

  • 25. Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation.
    Peddi VR, Kamath S, Munda R, Demmy AM, Alexander JW, First MR.
    Clin Transplant; 1998 Oct; 12(5):401-5. PubMed ID: 9787948
    [Abstract] [Full Text] [Related]

  • 26. Kidney transplantation with corticosteroid-free maintenance immunosuppression: a single center analysis of graft and patient survivals.
    Filipe R, Mota A, Alves R, Bastos C, Macário F, Figueiredo A, Roseiro A, Parada B, Sá H, Nunes P, Bastos M.
    Transplant Proc; 2009 Apr; 41(3):843-5. PubMed ID: 19376367
    [Abstract] [Full Text] [Related]

  • 27. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
    Guttmann RD, Flemming C.
    Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
    [Abstract] [Full Text] [Related]

  • 28. Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients.
    Yeung S, Tsang WK, Tong KL, Wong SH, Lee W, Tang HL, Chan HW, Chan AY.
    Transplant Proc; 2004 Sep; 36(7):2084-6. PubMed ID: 15518754
    [Abstract] [Full Text] [Related]

  • 29. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G, Döhler B, Collaborative Transplant Study.
    Transplantation; 2009 Mar 27; 87(6):795-802. PubMed ID: 19300179
    [Abstract] [Full Text] [Related]

  • 30. Rituximab induction therapy in highly sensitized kidney transplant recipients.
    Yin H, Wan H, Hu XP, Li XB, Wang W, Liu H, Ren L, Zhang XD.
    Chin Med J (Engl); 2011 Jul 05; 124(13):1928-32. PubMed ID: 22088448
    [Abstract] [Full Text] [Related]

  • 31. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW.
    Transplantation; 2003 Nov 15; 76(9):1289-93. PubMed ID: 14627905
    [Abstract] [Full Text] [Related]

  • 32. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, Ragni M, Fung JJ.
    Liver Transpl; 2002 Sep 15; 8(9):841-5. PubMed ID: 12200788
    [Abstract] [Full Text] [Related]

  • 33. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE, El-Dahshan K, Mahmoud K, Ismail AM, El-Baz M, Shokeir AA, Ghoneim MA.
    Exp Clin Transplant; 2008 Sep 15; 6(3):203-10. PubMed ID: 18954298
    [Abstract] [Full Text] [Related]

  • 34. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction.
    Patel SJ, Duhart BT, Krauss AG, Moore LW, Egidi MF, Amiri HS, Gaber LW, Gaber AO.
    Transplantation; 2008 Jul 27; 86(2):313-20. PubMed ID: 18645496
    [Abstract] [Full Text] [Related]

  • 35. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G, Tryphonopoulos P, Gaynor JJ, Guerra G, Sageshima J, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Powell RH, Ruiz P, Vianna R, Burke GW.
    Transplant Proc; 2016 Jul 27; 48(6):2006-10. PubMed ID: 27569936
    [Abstract] [Full Text] [Related]

  • 36. A pilot study of immunosuppression minimization after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
    Knight RJ, Kerman RH, McKissick E, Lawless A, Podder H, Katz S, Van Buren CT, Kahan BD.
    Transplant Proc; 2005 Oct 27; 37(8):3538-41. PubMed ID: 16298653
    [Abstract] [Full Text] [Related]

  • 37. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation.
    Budde K, Fritsche L, Mai I, Bauer S, Smettan S, Waiser J, Hofmann T, Hauser I, Reinke P, Neumayer HH.
    Int J Clin Pharmacol Ther; 1996 Nov 27; 34(11):493-7. PubMed ID: 8937932
    [Abstract] [Full Text] [Related]

  • 38. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A, Mazariegos G, Pokharna R, Parizhskaya M, Kashyap R, Kosmach-Park B, Smith A, Fung JJ, Reyes J.
    Transplantation; 2003 Apr 15; 75(7):1020-5. PubMed ID: 12698091
    [Abstract] [Full Text] [Related]

  • 39. Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus.
    Borrows R, Chusney G, Loucaidou M, James A, Stichbury J, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D.
    Ther Drug Monit; 2006 Apr 15; 28(2):269-73. PubMed ID: 16628143
    [Abstract] [Full Text] [Related]

  • 40. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
    Knight RJ, Kerman RH, McKissick E, Lawless A, Podder H, Katz S, Van Buren CT, Kahan BD.
    Clin Transplant; 2008 Apr 15; 22(5):645-50. PubMed ID: 18657156
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.